Zacks Investment ResearchTue, 28 Apr 2026 12:06:08 GMTImplied Volatility Surging for Black Diamond Therapeutics Stock OptionsBDTX+9.93%
Zacks Investment ResearchThu, 23 Apr 2026 16:30:37 GMTBDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go RightBDTX+9.93%
Zacks Investment ResearchThu, 23 Apr 2026 16:30:27 GMTBDTX and the CNS-Active EGFR Trend: Why C797S Is the PrizeBDTX+9.93%
Zacks Investment ResearchThu, 23 Apr 2026 16:25:31 GMTBlack Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and RisksBDTX+9.93%
Zacks Investment ResearchWed, 15 Apr 2026 16:30:23 GMTWhy Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?BDTX+9.93%
Zacks Investment ResearchThu, 09 Apr 2026 17:26:05 GMTBDTX and Brain Metastases: Why CNS Activity Could Matter in 2026BDTX+9.93%
Zacks Investment ResearchThu, 09 Apr 2026 17:21:10 GMTBlack Diamond Stock: Weighing Catalysts vs. ConcentrationBDTX+9.93%
Zacks Investment ResearchThu, 09 Apr 2026 17:16:14 GMTBDTX: What Silevertinib Data Say About EGFR NSCLC UpsideBDTX+9.93%
Seeking AlphaWed, 25 Mar 2026 12:53:10 GMTBlack Diamond Therapeutics: Market Is Yawning About These Data, But I See OpportunityBDTX+9.93%